621 results on '"Baeten, D"'
Search Results
2. Beneficial Immune Effects of Myeloid-Related Proteins in Kidney Transplant Rejection
3. Supplement to: Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis.
4. OP0100 IL-17A BLOCKADE MODULATES DISEASE SPECIFIC IMMUNE AND STROMAL PATHWAYS IN PERIPHERAL SPONDYLOARTHRITIS SYNOVITIS
5. Class 3 semaphorins modulate the invasive capacity of rheumatoid arthritis fibroblast-like synoviocytes: 7.10
6. Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study*
7. Identification of distinct polarized macrophage subsets in inflammatory arthritis
8. TNF and IL-6 differentially regulate the production of DKK-1, a master regulator of bone remodelling, by fibroblast-like synoviocytes
9. IL-17A producing mast cells as therapeutic target in spondyloarthritis
10. Tie2 signaling induces a pro-inflammatory and pro-chemotactic phenotype in differentiatedmacrophages, independently of macrophage polarization conditions: 1.26
11. Inflamed target tissue provides a specific niche for highly expanded T-cell clones in early human autoimmune disease
12. Needle Arthroscopy of the Knee with Synovial Biopsy Sampling: Technical Experience in 150 Patients
13. New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab
14. Constitutively active Rap1 protects from experimental autoimmune encephalomyelitis (EAE) by quantitative and qualitative modulation of auto-reactive T cells
15. Efficacité et sécurité d’emploi du bimekizumab dans la spondylarthrite ankylosante : résultats rapportés par les patients à 48 semaines dans une étude de phase IIb de détermination de la dose, randomisée, en double aveugle, contrôlée versus placebo
16. AB0114 IL12P40/IL23P40 BLOCKADE WITH USTEKINUMAB DECREASES THE INFLAMMATORY INFILTRATE AND MODULATES MOLECULAR PATHWAYS IN THE SYNOVIUM OF PSORIATIC ARTHRITIS PATIENTS
17. OP0105 EFFICACY AND SAFETY OF BIMEKIZUMAB IN ANKYLOSING SPONDYLITIS: 48-WEEK PATIENT-REPORTED OUTCOMES FROM A PHASE 2B, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY
18. Melanoma inhibitory activity, a biomarker related to chondrocyte anabolism, is reversibly suppressed by proinflammatory cytokines in rheumatoid arthritis
19. Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade
20. Bimekizumab for the treatment of moderate‐to‐severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double‐blind multicentre study*.
21. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints
22. A functional polymorphism of TIR-domain-containing adaptor protein is not associated with axial spondyloarthritis
23. Human meniscal proteoglycan metabolism in long-term tissue culture
24. Endogenous HLA–DR–restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint
25. Citrullination in extra-articular manifestations of rheumatoid arthritis
26. Synovial inflammation does not change in the absence of effective treatment: implications for the use of synovial histopathology as biomarker in early phase clinical trials in rheumatoid arthritis
27. Standardisation of synovial tissue infiltrate analysis: how far have we come? how much further do we need to go?
28. Interleukin-17A Is Produced by CD4+ but Not CD8+ T Cells in Synovial Fluid Following T Cell Receptor Activation and Regulates Different Inflammatory Mediators Compared to Tumor Necrosis Factor in a Model of Psoriatic Arthritis Synovitis
29. Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment
30. Functional haplotypes of PADI4: relevance for rheumatoid arthritis specific synovial intracellular citrullinated proteins and anticitrullinated protein antibodies
31. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis
32. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis
33. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy
34. Colon mucosa of patients both with spondyloarthritis and Crohn’s disease is enriched with macrophages expressing the scavenger receptor CD163
35. Prediction of arthritis using a modified Kohonen mapping and case based reasoning
36. Prediction of diagnosis in patients with early arthritis using a combined Kohonen mapping and instance-based evaluation criterion
37. Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumour necrosis factor α and interferon γ
38. Technical validation of cDNA based microarray as screening technique to identify candidate genes in synovial tissue biopsy specimens from patients with spondyloarthropathy
39. Tumour necrosis factor α independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules
40. Case Number 29: Ochronosis: synovial histopathological characteristics
41. Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumour necrosis factor and interferon
42. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?
43. Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: A histopathological study on the effect of infliximab on rheumatoid nodules
44. Tenosynovitis with acute onset: unexpected giant cell tumour of the tendon sheath
45. A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients
46. Repeated infusions of infliximab, a chimeric anti-TNFα monoclonal antibody, in patients with active spondyloarthropathy: one year follow up
47. Treatment of active spondyloarthropathy with infliximab, the chimeric monoclonal antibody to tumour necrosis factor α
48. The proportion of Th1 cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome
49. Culture of chondrocytes in alginate surrounded by fibrin gel: characteristics of the cells over a period of eight weeks
50. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFα
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.